CDKN2A and B-cell non-Hodgkin lymphoma: For example, Arf-/- mice transgenic for Eμ-myc developed aggressive B cell lymphomas with a dramatic acceleration in onset and increased mortality when compared to Arf+/+ Eμ-myc mice [5].